Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells

18 Aug 2020

Abstract excerpt

Chimeric antigen receptor (CAR) T cells represent a potentially curative therapy for patients with advanced hematological cancers; however, uncertainties surround the cell-intrinsic fitness as well as the exhaustion that restrict the capacity of CAR-T. Decitabine (DAC), a DNA demethylating agent, has been demonstrated to reverse exhaustion-associated DNA-methylation programs and to improve T cell responses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32973749
DOI: 10.3389/fimmu.2020.01787

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-CellsPMID 32973749Read ↗

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogrammingSemantic proximity Read ↗

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activitySemantic proximity Read ↗

TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDSSemantic proximity Read ↗

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemiaSemantic proximity Read ↗

Azacytidine restores T cell function in AML by modulating DNA methylationSemantic proximity Read ↗

Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapySemantic proximity Read ↗

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.Semantic proximity Read ↗

BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustionSemantic proximity Read ↗

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic ReprogrammingSemantic proximity Read ↗

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity.Semantic proximity Read ↗

Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemiaSemantic proximity Read ↗

Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.